Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal Sacituzumab Tirumotecan in EGFR-TKI-Resistant NSCLC with Leptomeningeal Metastasis
NCT07702305Phase 1Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jun 2026
- Primary completion
- Dec 2027
01
Overview
Phase 1, open-label, single-arm trial of sacituzumab tirumotecan in non-small cell lung cancer (NSCLC) and leptomeningeal metastasis (LM), sponsored by Henan Cancer Hospital. Primary endpoints: Drug Safety and Recommended Phase 2 Dose at 21 days. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
non-small cell lung cancer (NSCLC)leptomeningeal metastasis (LM)
Beyond the preview
Go deeper on NCT07702305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07702305.